Immuno-Oncology | Specialty

Optimizing Frontline Immunotherapy in NSCLC

November 15th 2016

Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.

Expert Discusses Next Steps With Immunotherapy in Lung Cancer

November 15th 2016

Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.

Nivolumab/Ipilimumab Combo Highly Effective for Pretreated Metastatic Urothelial Carcinoma

November 14th 2016

The combination of nivolumab and ipilimumab led to a high response rate and improved overall survival versus historical controls for patients with pretreated metastatic urothelial carcinoma.

Sponsored Content: The Changing Paradigm of Cancer Research

November 14th 2016

Immuno-oncology is among the most discussed topics in cancer research, but many are unaware of the science behind this class of treatments. Learn how it works.

Preclinical Studies Help to Illuminate Immunotherapy's Role in HCC

November 14th 2016

Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.

Dr. Tim F. Greten on Immunotherapy in HCC

November 14th 2016

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute (NCI), discusses the potential for immunotherapy in hepatocellular carcinoma (HCC).

Biomarkers Define Future Age of Immunotherapy in Cancer

November 13th 2016

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.

Pembrolizumab OS Benefit Sets New Benchmark in Second-Line Bladder Cancer

November 13th 2016

Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.

Lirilumab/Nivolumab Combo Highly Effective in Head and Neck Cancer

November 13th 2016

The combination of lirilumab and nivolumab resulted in an objective response rate of 24.1% in patients with squamous cell carcinoma of the head and neck.

Dr. Anne Chiang on Molecular Testing in Lung Cancer Treatment Planning

November 13th 2016

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer

November 13th 2016

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.

Dr. Vokes on Nivolumab, Pembrolizumab Approvals in Head and Neck Cancer

November 12th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the FDA approvals of the PD-L1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.

Immunotherapy Combo Regimens on Horizon in Lymphoma

November 12th 2016

Nivolumab (Opdivo) may be the only checkpoint inhibitor that is approved by the FDA as a treatment of patients with Hodgkin lymphoma, but other immunotherapies—alone and in combination with other novel agents—are emerging in other indications.

Future Directions for Antiangiogenic Therapy in Lung Cancer

November 11th 2016

Promising Anti-VEGF Combinations for NSCLC

November 11th 2016

Resistance to Antiangiogenic Therapy in Lung Cancer

November 11th 2016

Antiangiogenic Antibodies vs TKIs in NSCLC

November 11th 2016

Blocking VEGFR2 vs VEGFA or VEGFB in Lung Cancer

November 11th 2016

Sequencing Therapies in Advanced Lung Adenocarcinoma

November 11th 2016

Patient Selection for Ramucirumab in NSCLC

November 11th 2016